In clinical studies in which TYMLOS was administered once daily to postmenopausal women with osteoporosis: Early increases in a bone formation marker peaked
at month 11

P1NP* bone formation marker levels were maintained above baseline throughout treatment1

Bone turnover marker levels at peak and at end of study with TYMLOS1

Bone turnover marker levels - p1np-levels

Serum procollagen type 1 N-propeptide.1

Serum collagen type 1 cross-linked C-telopeptide.1

See the abaloparatide
mechanism of action video

Reference: 1. TYMLOS® [prescribing information]. Waltham, MA: Radius Health, Inc; 2018.

This site is intended for HCPs in the United States.

All other trademarks are the property of their respective owners.

© 2019 Radius Health, Inc.   All rights reserved.    10/19.   TYM-US-02916

This site is intended for HCPs in the United States.
TYMLOS is a registered trademark of Radius Health, Inc.
All other trademarks are the property of their respective owners.

© 2019 Radius Health, Inc.
All rights reserved. 10/19.
TYM-US-02916

Back to Top